


PHARMACEUTICAL 2017

Seres Therapeutics Inc. Rank 155 of 292











Seres Therapeutics Inc. Rank 155 of 292

The relative strengths and weaknesses of Seres Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Seres Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Seres Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 107% points.

The company's Economic Capital Ratio, given in the ranking table, is 66%, being 63% points above the market average of 2.9%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 198,369              |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 0                    |
| Liabilities, Current                        | 30,457               |
| Liabilities, Non-Current                    | 0                    |
| Other Assets                                | 38,152               |
| Other Compr. Net Income                     | -179                 |
| Other Expenses                              | 0                    |
| Other Liabilities                           | 109,558              |
| Other Net Income                            | 1,260                |
| Other Revenues                              | 21,766               |
| Property and Equipment                      | 36,125               |
| Research and Development                    | 81,989               |
| Selling, General and Administrative Expense | 32,616               |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 272,646              |
| Liabilities              | 140,015              |
| Expenses                 | 114,605              |
| Revenues                 | 21,766               |
| Stockholders Equity      | 132,631              |
| Net Income               | -91,579              |
| Comprehensive Net Income | -91,668              |
| Economic Capital Ratio   | 66%                  |

